edd/Vaccine
WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.Sparrow E, Adetifa I, Chaiyakunapruk N, Cherian T, Fell DB, Graham BS, Innis B, Kaslow DC, Karron RA, Nair H, Neuzil KM, Saha S, Smith PG, Srikantiah P, Were F, Zar HJ, Feikin D
Vaccine, (2022). 40:3506-3510
Unmet need for COVID-19 vaccination coverage in Kenya.Muchiri SK, Muthee R, Kiarie H, Sitienei J, Agweyu A, Atkinson PM, Edson Utazi C, Tatem AJ, Alegana VA
Vaccine, (2022). 40:2011-2019
Coverage and timeliness of vaccination and the validity of routine estimates: Insights from a vaccine registry in Kenya.Adetifa IMO, Karia B, Mutuku A, Bwanaali T, Makumi A, Wafula J, Chome M, Mwatsuma P, Bauni E, Hammitt LL, Mataza C, Tabu C, Kamau T, Williams TN, Scott JAG
Vaccine, (2018). 36:7965-7974
Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data.Ojal J, Flasche S, Hammitt LL, Akech D, Kiti MC, Kamau T, Adetifa I, Nurhonen M, Scott JAG, Auranen K
Vaccine, (2017). 35:4561-4568
Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls.Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, Feikin DR, Groome MJ, Hajjeh RA, Johnson HL, Madhi SA, Mulholland K, O'Brien KL, Parashar UD, Patel MM, Rodrigues LC, Santosham M, Scott JA, Smith PG, Sommerfelt H, Tate JE, Victor JC, Whitney CG, Zaidi AK, Zell ER
Vaccine, (2017). 35:3295-3302
Case-control vaccine effectiveness studies: Data collection, analysis and reporting results.Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, Feikin DR, Groome MJ, Hajjeh RA, Johnson HL, Madhi SA, Mulholland K, O'Brien KL, Parashar UD, Patel MM, Rodrigues LC, Santosham M, Scott JA, Smith PG, Sommerfelt H, Tate JE, Victor JC, Whitney CG, Zaidi AK, Zell ER
Vaccine, (2017). 35:3303-3308
Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach.Pan-Ngum W, Kinyanjui T, Kiti M, Taylor S, Toussaint JF, Saralamba S, Van Effelterre T, Nokes DJ, White LJ
Vaccine, (2017). 35:403-409
Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya.Nyiro JU, Sande C, Mutunga M, Kiyuka PK, Munywoki PK, Scott JA, Nokes DJ
Vaccine, (2015). 33:1797-801
The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants.Sande CJ, Cane PA, Nokes DJ
Vaccine, (2014). 32:4726-9
Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group.Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare KM, Henao-Restrepo AM, Leach AJ, Klugman KP, Porter BD, Sa-Leao R, Scott JA, Nohynek H, O'Brien KL, WHO Pneumococcal Carriage Working Group
Vaccine, (2013). 32:165-79
Strategic priorities for respiratory syncytial virus (RSV) vaccine development.Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS
Vaccine, (2013). 31 Suppl 2:B209-15
Spatial and socio-demographic predictors of time-to-immunization in a rural area in Kenya: Is equity attainable?.Moisi JC, Kabuka J, Mitingi D, Levine OS, Scott JA
Vaccine, (2010). 28:5725-30
Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules.Wilson JN, Nokes DJ, Medley GF, Shouval D
Vaccine, (2007). 25:3705-12
The preventable burden of pneumococcal disease in the developing world.Scott JA
Vaccine, (2007). 25:2398-405
High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Williams TN, Mwangi TW, Marsh K
Vaccine, (2006). 24:4233-46
Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria.Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, Lanar DE, Remarque E, Ross A, Williams TN, Mwambingu G, Lowe B, Conway DJ, Marsh K
Vaccine, (2004). 23:718-28
